GlassScriptPhysician profile
Samson S Sheih
NPI 1700880424
$13,278.89
in general payments reported to CMS, 2019-2025
45 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,747 · 2020: $1,724 · 2021: $2,166 · 2022: $2,070 · 2023: $1,913 · 2024: $1,883 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,526 · Education: $45.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,526.09 |
| Education | $45.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,559.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,464.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,368.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,245.72 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,157.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,032.84 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $646.45 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $540.28 | 2019-2022 | |
| Pfizer INC. | $438.98 | 2019-2025 | |
| Amgen INC. | $397.93 | 2019-2025 | Evenity, Repatha, Otezla |
| Dexcom, INC. | $333.17 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $281.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $275.48 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $268.06 | 2023-2025 | |
| Allergan, INC. | $221.96 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samson Sheih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.